Lead Plaintiff Deadline is April 26, 2019

NEW YORK, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors who purchased or otherwise acquired AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) securities between August 4, 2016 and January 31, 2019 (the “Class Period”), inclusive.

Investors who purchased shares of AVEO Pharmaceuticals, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website www.whafh.com.

If you have incurred losses in the shares of AVEO Pharmaceuticals, Inc., you may, no later than April 26, 2019, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in AVEO Pharmaceuticals, Inc.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

The filed complaint alleges that throughout the class period defendants made false and/or misleading statements and/or failed to disclose that:

• the TIVO-3 trial was inadequately designed to address the overall survival concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented back in the June 2013;
   
• tivozanib had insufficient survival data to obtain U.S. Food and Drug Administration (“FDA”) approval following its initial rejection by the FDA in 2013;
   
• this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and
   
• as a result, AVEO’s public statements were materially false and misleading at all relevant times.

Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.